Details for Patent: 6,787,531

✉ Email this page to a colleague

Summary for Patent: 6,787,531

Title:	Pharmaceutical composition for use as a contraceptive
Abstract:	A pharmaceutical composition comprises, as a first active agent, 6.beta.,7.beta.; 15.beta.,16.beta.-dimethylene-3-oxo-17.alpha.-pregn-4-ene-21,17-carbolacto ne (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17.alpha.-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients. In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing ethinylestradiol alone.
Inventor(s):	Hilman; Juergen (Berlin, DE), Heil; Wolfgang (Berlin, DE), Lipp; Ralph (Berlin, DE), Heithecker; Renate (Berlin, DE), Huempel; Michael (Berlin, DE), Tack; Johannes W. (Berlin, DE)
Assignee:	Schering AG (Berlin, DE)
Application Number:	09/654,227
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,787,531
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form; Device;

Drugs Protected by US Patent 6,787,531

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 6,787,531

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1214076	⤷ Sign Up	C01214076/01	Switzerland	⤷ Sign Up
European Patent Office	1380301	⤷ Sign Up	CA 2009 00017	Denmark	⤷ Sign Up
European Patent Office	1380301	⤷ Sign Up	SPC019/2009	Ireland	⤷ Sign Up
European Patent Office	1214076	⤷ Sign Up	SZ 49/2008	Austria	⤷ Sign Up
European Patent Office	1214076	⤷ Sign Up	49/2008	Austria	⤷ Sign Up
European Patent Office	1380301	⤷ Sign Up	2009C/007	Belgium	⤷ Sign Up
Argentina	025443	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.